获批用于基因组学适应症的肿瘤药物总生存期分析
研究检索2006至2020年美国食品药品监督管理局(FDA)批准的53种用于92个基因组学适应症的抗肿瘤药物,发现55%的适应症有随机研究评估总生存期(OS)获益,其中仅22种显示OS改善;57%评估无进展生存期(PFS),其中51种显示PFS改善。
要点
- 2006至2020年FDA批准53种药物用于92个基因组学适应症。
- 55%的基因组学适应症有随机研究评估OS,其中仅22种显示OS改善。
- 57%的适应症评估PFS,其中51种显示PFS改善。
核心结论
- 尽管这类药物广受关注且许多药物显示出显著的缓解率,仍需进一步试验或上市后研究以明确其对生存和生活质量的影响、获益幅度及成本效益。
研究设计与样本
- 检索2006至2020年美国食品药品监督管理局(FDA)批准的所有基因组学适应症药物,并在PubMed检索评估总生存期(OS)或无进展生存期(PFS)的随机研究。
主要发现
- 共发现53种药物获批用于92个独特适应症。
- 50种药物(55%)的基因组学适应症有随机研究评估OS获益,其中仅22种显示OS改善。
- 52种药物(57%)的适应症评估PFS获益,其中51种研究显示PFS改善。
- 获批用于BRAF V600黑色素瘤的药物较获批用于ALK非小细胞肺癌的药物更常显示OS改善。
- OS改善的中位值为4.7个月(范围1.5个月至49.1个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Drug approvals for genome-informed indications have been increasing in recent years, but it is unknown how many of them have demonstrated an improvement in overall survival (OS). We assessed the frequency of approved genome-informed drugs demonstrating improvements in OS and progression-free survival (PFS) and whether the frequencies differed by cancer type. MATERIALS AND METHODS: We searched all Food and Drug Administration approvals from 2006 to 2020, and for each drug that was approved for a genomic indication, we then searched on PubMed for randomised studies examining OS or PFS. RESULTS: We found 53 drugs approved for 92 unique indications from 2006 to 2020. We found that 50 drugs (55%) approved for a genomic indication had a randomised study evaluating OS benefit, and of those, only 22 demonstrated an improvement in OS. Similarly, 52 drugs (57%) evaluated PFS benefit, and 51 of these studies demonstrated an improvement in PFS. Drugs approved for BRAF V600 melanoma demonstrated an improvement in OS more often than drugs approved for ALK non-small cell lung cancer. The median improvement in OS was 4.7 months (range 1.5 months-49.1 months). CONCLUSION: Although there is widespread enthusiasm for this class of agents, and many demonstrate impressive response rates, further trials or post-marketing studies are needed to ascertain the impact on survival and quality of life, the magnitude of these gains, and the cost-effectiveness of these agents.
引用
- Haslam A, Kim MS, Prasad V, et al. Overall survival for oncology drugs approved for genomic indications. Eur J Cancer. 2021. PMID: 34819251. doi:10.1016/j.ejca.2021.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。